Observe Medical (OBSRV) Q4 2024 earnings summary

Executive summary

• 2024 marked a transition year with the launch of UnoMeter Safeti Plus, the most revenue-generating product in the Convatec portfolio, and the completion of a new manufacturing platform and regulatory journey.

• The company re-established its global distribution network, expanded product offerings, and completed the commercialization of the full Convatec UnoMeter portfolio.

• Strategic restructuring included transferring Nordic distribution contracts to Vingmed and focusing on international market expansion.

• Significant cost reductions were achieved through workforce downsizing and office closures.

• The company faces material uncertainty regarding its ability to continue as a going concern due to insufficient working capital.

Financial highlights

• H2 2024 revenue was NOK 5.4 million, down NOK 10.7 million year-over-year; FY 2024 revenue was NOK 18.5 million, down NOK 9.5 million year-over-year.

• Gross profit for H2 2024 was negative NOK 1.9 million (gross margin -35.3%), mainly due to a NOK 3.1 million inventory write-down and lower-margin product mix.

• Adjusted EBITDA for H2 2024 was negative NOK 14.3 million; FY 2024 adjusted EBITDA was negative NOK 26.9 million.

• Result for H2 2024 was negative NOK 104.5 million, including a NOK 69.8 million goodwill impairment; EPS for H2 2024 was negative NOK 0.78.

• Equity at year-end was NOK 24.1 million (equity ratio 16.2%), down from NOK 112.1 million (45.8%) at end-2023.

Outlook and guidance

• UnoMeter Safeti Plus is expected to drive significant revenue growth, with NOK 5 million in firm orders received within the first month of launch.

• The company aims to reclaim market leadership in urine measurement and plans to launch new products, including UnoMeter Safeti Max and Sippi, in 2025.

• Management estimates NOK 100 million in UnoMeter family revenue over the next 12 months.

• Ongoing discussions with Fresenius Medical Care for Biim ultrasound probe may impact future revenue; further evaluation continues into 2025.

• Strategic focus remains on global expansion, product innovation, and potential M&A opportunities.